Juntendo Medical Journal
Online ISSN : 2188-2126
Print ISSN : 2187-9737
ISSN-L : 2187-9737
Current Topics: Current Research Topics in Tropical Diseases; Towards Successful Control and Elimination
Preclinical Studies on a New Vaccine Formulation of BK-SE36, a Malaria Vaccine Candidate
NIRIANNE MARIE Q. PALACPACTAKAHIRO TOUGANTOSHIHIRO HORII
Author information
JOURNAL FREE ACCESS

2015 Volume 61 Issue 4 Pages 360-369

Details
Abstract

An effective blood-stage vaccine remains elusive but necessary if we are to reduce malaria morbidity and mortality. The SE36 antigen derived from serine repeat antigen 5 (SERA5) of Plasmodium falciparum remains a promising blood-stage malaria vaccine candidate. The protective efficacy of BK-SE36, SE36 recombinant protein and aluminum hydroxide gel, is continuously being studied in clinical trials. However, the efficacy of BK-SE36 may still be improved with the use of DNA sequences containing CpG motifs that can selectively promote cellular and/or humoral immune responses. Preclinical studies in non-human primates show promising results. A clinical trial of the vaccine candidate BK-SE36/CpG in a malaria-exposed population is awaited as this can give valuable clues on the immune responses towards K3 CpG formulation in malaria-endemic populations.

Content from these authors
Previous article Next article
feedback
Top